To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00141336

Enrollment

750

Registered

2005-09-01

Start date

1999-11-30

Completion date

2005-07-31

Last updated

2007-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seizure Disorder, Partial

Brief summary

To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.

Interventions

DRUGPregabalin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have met the inclusion criteria for preceding double-blind study * Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

* Cannot have absence seizures

Design outcomes

Primary

Measure	Time frame
Safety Tolerability	—

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026